View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsPieris Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6Pieris Pharmaceuticals은 연평균 5.2%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 11.9%의 비율로 감소했습니다.핵심 정보5.24%순이익 성장률16.38%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률-11.91%자기자본이익률-98.06%순이익률-1,179.96%최근 순이익 업데이트30 Sep 2024최근 과거 실적 업데이트Reported Earnings • Nov 15Third quarter 2024 earnings released: US$2.19 loss per share (vs US$8.70 loss in 3Q 2023)Third quarter 2024 results: US$2.19 loss per share (improved from US$8.70 loss in 3Q 2023). Net loss: US$2.89m (loss narrowed 73% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 16Second quarter 2024 earnings released: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)Second quarter 2024 results: US$2.76 loss per share (down from US$3.63 profit in 2Q 2023). Net loss: US$3.59m (down 190% from profit in 2Q 2023).Reported Earnings • May 17First quarter 2024 earnings released: US$3.96 loss per share (vs US$14.15 loss in 1Q 2023)First quarter 2024 results: US$3.96 loss per share (improved from US$14.15 loss in 1Q 2023). Revenue: US$53.0k (down 97% from 1Q 2023). Net loss: US$4.89m (loss narrowed 63% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 31Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)Full year 2023 results: US$0.27 loss per share (improved from US$0.45 loss in FY 2022). Revenue: US$42.8m (up 65% from FY 2022). Net loss: US$24.5m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 17Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2023 results: US$0.11 loss per share. Revenue: US$19.5m (up 264% from 3Q 2022). Net loss: US$10.8m (loss widened 10% from 3Q 2022). Revenue is expected to decline by 81% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%.Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$0.045 (up from US$0.14 loss in 2Q 2022). Revenue: US$20.1m (up 442% from 2Q 2022). Net income: US$3.98m (up US$14.3m from 2Q 2022). Profit margin: 20% (up from net loss in 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 17% during the next year, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesReported Earnings • Nov 15Third quarter 2024 earnings released: US$2.19 loss per share (vs US$8.70 loss in 3Q 2023)Third quarter 2024 results: US$2.19 loss per share (improved from US$8.70 loss in 3Q 2023). Net loss: US$2.89m (loss narrowed 73% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.공시 • Nov 07Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024.Reported Earnings • Aug 16Second quarter 2024 earnings released: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)Second quarter 2024 results: US$2.76 loss per share (down from US$3.63 profit in 2Q 2023). Net loss: US$3.59m (down 190% from profit in 2Q 2023).공시 • Jul 25Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction.Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction on July 23, 2024. The provisions for calculating the Exchange Ratio are set forth in the Merger Agreement and assume a valuation for Palvella equal to $95.0 million and a valuation for Pieris equal to $21.0 million. Under the terms of the merger agreement, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. Upon termination of the Merger Agreement under specified circumstances, Pieris may be required to pay Palvella a termination fee of $1.0 million and Palvella may be required to pay Pieris a termination fee of $2.0 million. The transactions contemplated by the merger agreement have been unanimously approved by the boards of directors of both companies. The transaction is subject to approvals by the stockholders of each company, consummation of the Concurrent Financing, the effectiveness of a registration statement to be filed with the SEC to register the shares of Pieris common stock to be issued in connection with the merger, and other customary closing conditions. TD Cowen is serving as lead placement agent and Cantor is serving as a placement agent for Palvella's planned concurrent financing. Christopher S. Miller of Troutman Pepper Hamilton Sanders LLP is serving as legal counsel to Palvella. Cooley LLP is serving as legal counsel to the placement agents. Stifel is serving as the exclusive financial advisor to Pieris and William C. Hicks, Marc D. Mantell and Scott Dunberg of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. is serving as legal counsel to Pieris. Stifel, Nicolaus & Company, Incorporated acted as fairness opinion provider to Pieris. Computershare Trust Company, National Association acted as transfer agent to Pieris.New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 27% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (US$10.5m market cap).분석 기사 • Jul 11The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%Unfortunately for some shareholders, the Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has dived 30% in the...Reported Earnings • May 17First quarter 2024 earnings released: US$3.96 loss per share (vs US$14.15 loss in 1Q 2023)First quarter 2024 results: US$3.96 loss per share (improved from US$14.15 loss in 1Q 2023). Revenue: US$53.0k (down 97% from 1Q 2023). Net loss: US$4.89m (loss narrowed 63% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.분석 기사 • Apr 21Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price PlungePieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders won't be pleased to see that the share price has had a very...공시 • Apr 21Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price RequirementPieris Pharmaceuticals, Inc. announced that its board of directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's existing trading symbol ‘PIRS’. The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 720795202. The Company filed a Certificate of Change with the Nevada Secretary of State on April 18, 2024 to effect the reverse split.Reported Earnings • Mar 31Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)Full year 2023 results: US$0.27 loss per share (improved from US$0.45 loss in FY 2022). Revenue: US$42.8m (up 65% from FY 2022). Net loss: US$24.5m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.분석 기사 • Mar 19We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Dec 18Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%Unfortunately for some shareholders, the Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has dived 27% in the...Reported Earnings • Nov 17Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2023 results: US$0.11 loss per share. Revenue: US$19.5m (up 264% from 3Q 2022). Net loss: US$10.8m (loss widened 10% from 3Q 2022). Revenue is expected to decline by 81% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%.분석 기사 • Aug 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$0.045 (up from US$0.14 loss in 2Q 2022). Revenue: US$20.1m (up 442% from 2Q 2022). Net income: US$3.98m (up US$14.3m from 2Q 2022). Profit margin: 20% (up from net loss in 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 17% during the next year, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.공시 • Jul 14Pieris Pharmaceuticals, Inc. Announces Executive ChangesPieris Pharmaceuticals, Inc. announced on July 13, 2023, Ahmed Mousa, the Senior Vice President, Chief Business Officer, General Counsel & Corporate Secretary of the company, gave notice that he will resign from the company effective September 11, 2023 in order to become chief executive officer of Vicore Pharma Holding AB. Mr. Mousa is expected to serve as a strategic advisor to the Company for a transition period thereafter, subject to a mutual agreement of terms in the near future. Mr. Mousa’s resignation is not a result of any disagreement with the Company or any other entity or on any matter relating to the operations, policies (including accounting or financial policies) or practices of the company. Following Mr. Mousa’s departure, Stephen Yoder, the company’s chief executive officer and President will oversee corporate and business development at the company.New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$49m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 8.5% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$13.6m market cap).New Risk • Jun 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 8.5% per year for the foreseeable future. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$49m). Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$21.4m market cap).공시 • May 22+ 1 more updatePieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International ConferencePieris Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company's inhaled connective tissue growth factor (CTGF) antagonist program, PRS-220, for idiopathic pulmonary fibrosis (IPF) at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023. The poster will be presented on May 21, 2023, from 11:30 AM to 1:15 PM (Session A67, P1052) and demonstrates that PRS-220 achieved proof of concept in a silica-induced lung fibrosis mouse model when delivered to the lung by inhalation and outperformed a systemically administered CTGF-targeting monoclonal antibody, reinforcing the transformative potential of a local intervention in this pathway. The poster also includes preclinical data demonstrating a favorable profile of PRS-220 for inhaled delivery and CTGF targeting in the lung, including a superior lung biodistribution profile compared to a systemically administered anti-CTGF monoclonal antibody, a lung PK profile supporting once or twice daily dosing in humans, and desired aerosol performance upon nebulization to effectively target pulmonary tissue of interest. PRS-220 is an inhaled Anticalin protein targeting CTGF for the treatment of IPF and other fibrotic lung diseases. Previously reported preclinical data for PRS-220 demonstrated superior on-target potency compared to pamrevlumab, an intravenously infused CTGF antagonist in late-stage clinical development. Pieris continues to benefit from a meaningful grant from the Bavarian government, which supports early-stage development of this program.Major Estimate Revision • May 17Consensus revenue estimates fall by 31%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$17.4m to US$12.0m. Forecast losses increased from -US$0.64 to -US$0.705 per share. Biotechs industry in the US expected to see average net income decline 85% next year. Consensus price target of US$7.00 unchanged from last update. Share price fell 6.0% to US$0.80 over the past week.분석 기사 • May 15Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts DramaticallyThe latest analyst coverage could presage a bad day for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), with the analysts...Reported Earnings • May 10First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)First quarter 2023 results: US$0.18 loss per share (further deteriorated from US$0.069 loss in 1Q 2022). Revenue: US$1.94m (down 82% from 1Q 2022). Net loss: US$13.2m (loss widened 158% from 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.공시 • May 05Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)Pieris Pharmaceuticals, Inc. announced the successful safety review of the 10 mg dry powder dose safety cohort from the ongoing multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated elarekibep (PRS-060/AZD1402). The successful review of the 10 mg dose provides additional data supporting the elarekibep safety profile and enables doses of 10 mg or less to be evaluated in future clinical trials. Elarekibep is an IL-4 receptor alpha inhibitor under development in collaboration with AstraZeneca for the treatment of moderate-to-severe asthma. Pieris previously announced the successful completion of the safety review for the 1 mg and 3 mg doses, triggering the efficacy portion of the study, which is ongoing at the 3 mg dose. Upon completion of the phase 2a study and availability of topline data, which Pieris expects to be reported by mid-2024, the Company will have a co-development option for this program with AstraZeneca. For this safety review, 13 asthma patients, controlled on standard of care (medium dose inhaled corticosteroids with long-acting beta agonists), received elarekibep twice daily over four weeks to establish the safety profile and pharmacokinetics of the dry powder formulation of elarekibep at the 10 mg dose. Following completion of enrollment and observation, AstraZeneca evaluated, compared to placebo, the incidence of adverse events, changes in laboratory markers (immuno-biomarkers, clinical chemistry, and hematology), and forced expiratory volume in one second.분석 기사 • Apr 17Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price PlungeThe Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has fared very poorly over the last month, falling by a...Reported Earnings • Mar 31Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)Full year 2022 results: US$0.45 loss per share (improved from US$0.71 loss in FY 2021). Revenue: US$25.9m (down 18% from FY 2021). Net loss: US$33.3m (loss narrowed 27% from FY 2021). Products in clinical trials Phase I: 3 Phase II: 1 Revenue is expected to decline by 41% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 13%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.공시 • Jan 11Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)Pieris Pharmaceuticals, Inc. announced that the Company has achieved a $5 million milestone from Seagen. The milestone is based on dosing the first patient in a Seagen-sponsored phase 1 study of SGN-BB228 (PRS-346), a novel bispecific antibody-Anticalin molecule (Mabcalin™) that is designed to provide a potent costimulatory bridge between tumor-specific T cells and CD228 expressing tumor cells. The Seagen-sponsored (NCT05571839) open-label phase 1 study is evaluating the safety and tolerability of SGN-BB228 in patients with advanced melanoma and other solid tumors. Secondary endpoints in the study include pharmacokinetics and antitumor activity. This program is one of three ongoing immuno-oncology programs with Seagen and preclinical data were recently presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston. Pieris has an opt-in option to a U.S. co-promotion for one program in the collaboration.분석 기사 • Dec 31Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Price Target Changed • Nov 16Price target decreased to US$7.00Down from US$8.00, the current price target is provided by 1 analyst. New target price is 593% above last closing price of US$1.01. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$0.47 next year compared to a net loss per share of US$0.71 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 03Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: US$0.13 loss per share (improved from US$0.24 loss in 3Q 2021). Revenue: US$5.37m (up 32% from 3Q 2021). Net loss: US$9.74m (loss narrowed 41% from 3Q 2021). Revenue is expected to decline by 17% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.Major Estimate Revision • Aug 11Consensus revenue estimates fall by 48%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$45.7m to US$23.7m. Forecast losses increased from -US$0.41 to -US$0.47 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target down from US$8.00 to US$7.00. Share price fell 9.3% to US$1.56 over the past week.분석 기사 • Aug 10Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS PrognosticationsThe latest analyst coverage could presage a bad day for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), with the covering...Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: US$0.14 loss per share (up from US$0.25 loss in 2Q 2021). Revenue: US$3.70m (up 13% from 2Q 2021). Net loss: US$10.3m (loss narrowed 33% from 2Q 2021). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Over the next year, revenue is expected to shrink by 45% compared to a 46% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.Seeking Alpha • Aug 04Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77MPieris Pharmaceuticals press release (NASDAQ:PIRS): Q2 GAAP EPS of -$0.14 misses by $0.03. Revenue of $3.7M (+12.5% Y/Y) misses by $6.77M. Cash, equivalents, and investments totaled $80.9 million for the quarter ended June 30, 2022, compared to a cash and cash equivalents balance of $117.8 million for the quarter ended December 31, 2021.. Shares +4.95% PM.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.069 loss per share. Revenue: US$11.0m (down 30% from 1Q 2021). Net loss: US$5.10m (loss widened 22% from 1Q 2021). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 72%, compared to a 25% growth forecast for the industry in the US.Major Estimate Revision • May 12Consensus estimates of losses per share improve by 23%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from US$45.2m to US$45.7m. EPS estimate increased from -US$0.53 per share to -US$0.41 per share. Biotechs industry in the US expected to see average net income decline 44% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 34% to US$1.67 over the past week.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 03Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.71 loss per share (down from US$0.68 loss in FY 2020). Revenue: US$31.4m (up 7.1% from FY 2020). Net loss: US$45.7m (loss widened 23% from FY 2020). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 19%. Over the next year, revenue is forecast to grow 125%, compared to a 71% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Seeking Alpha • Jan 09Pieris: Early Stage Developer Of Novel Asset ClassPieris develops anticalin-based therapies. These are proteins that are smaller than most, enabling inhaled formulations and better tissue penetration. A number of big pharma are interested.분석 기사 • Dec 15We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$4.06m (up 38% from 3Q 2020). Net loss: US$16.5m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Board Change • Nov 03Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Oct 27Progress At Pieris PharmaceuticalsToday, we revisit a promising small cap biopharma concern named Pieris Pharmaceuticals for the first time in just over two years. The company has made some progress advancing its pipeline and recently signed a potentially significant collaboration deal with Genentech. A full investment analysis follows in the paragraphs below.Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$3.29m (down 71% from 2Q 2020). Net loss: US$15.5m (loss widened 213% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Major Estimate Revision • Aug 05Consensus revenue estimates increase to US$32.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$21.8m to US$32.5m. Forecast losses expected to reduce from -US$0.90 to -US$0.78 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target of US$8.50 unchanged from last update. Share price rose 9.9% to US$3.76 over the past week.분석 기사 • Aug 05Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) ForecastsShareholders in Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) may be thrilled to learn that the analysts have just...Price Target Changed • Jul 06Price target increased to US$8.50Up from US$7.50, the current price target is an average from 3 analysts. New target price is 132% above last closing price of US$3.66. Stock is up 13% over the past year.공시 • Jun 28Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth IndexPieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index분석 기사 • Jun 19We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A MicroscopeShareholders will probably not be too impressed with the underwhelming results at Pieris Pharmaceuticals, Inc...Major Estimate Revision • May 24Consensus revenue estimates fall to US$22.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$29.7m to US$22.0m. Forecast losses increased from -US$0.69 to -US$0.90 per share. Biotechs industry in the US expected to see average net income decline 7.2% next year. Consensus price target down from US$9.00 to US$7.50. Share price was steady at US$1.93 over the past week.분석 기사 • May 22Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) EstimatesMarket forces rained on the parade of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders today, when the...Price Target Changed • May 20Price target decreased to US$7.50Down from US$9.00, the current price target is an average from 2 analysts. New target price is 308% above last closing price of US$1.84. Stock is down 40% over the past year.분석 기사 • May 19Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • May 18First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$15.6m (up 18% from 1Q 2020). Net loss: US$4.17m (loss widened 16% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.Reported Earnings • Apr 01Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$29.3m (down 37% from FY 2019). Net loss: US$37.2m (loss widened 32% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.분석 기사 • Apr 01Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This WeekCelebrations may be in order for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders, with the analysts...Is New 90 Day High Low • Mar 09New 90-day low: US$2.41The company is down 11% from its price of US$2.70 on 08 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$1.60 per share.분석 기사 • Mar 08Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks LikeEvery investor in Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) should be aware of the most powerful shareholder groups...Is New 90 Day High Low • Feb 11New 90-day high: US$3.19The company is up 20% from its price of US$2.65 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period.분석 기사 • Feb 01We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Price Target Changed • Jan 30Price target raised to US$9.00Up from US$8.00, the current price target is an average from 4 analysts. The new target price is 254% above the current share price of US$2.54. As of last close, the stock is down 31% over the past year.분석 기사 • Dec 28How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?While it may not be enough for some shareholders, we think it is good to see the Pieris Pharmaceuticals, Inc...Is New 90 Day High Low • Dec 16New 90-day high: US$3.13The company is up 9.0% from its price of US$2.88 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.분석 기사 • Dec 02How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?Steve Yoder has been the CEO of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) since 2014, and this article will examine...Major Estimate Revision • Nov 11Analysts lower revenue estimates to US$30.5mThe 2020 consensus revenue estimate decreased from US$42.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$0.48 to -US$0.64 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.6% next year. The consensus price target was lowered from US$8.00 to US$7.67. Share price is up 13% to US$2.82 over the past week.Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.26 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$2.94m (down 81% from 3Q 2019). Net loss: US$14.3m (loss widened 451% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.Analyst Estimate Surprise Post Earnings • Nov 07Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 80%. Earnings per share (EPS) exceeded analyst estimates by 111%. Over the next year, revenue is expected to shrink by 32% compared to a 309% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Sep 22New 90-day low: US$2.33The company is down 28% from its price of US$3.22 on 24 June 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.매출 및 비용 세부 내역Pieris Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:PIRS 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 241-1613030 Jun 2421-2417031 Mar 2441-1617031 Dec 2343-2517030 Sep 2347-2819030 Jun 2333-2716031 Mar 2317-4116031 Dec 2226-3316030 Sep 2228-3516030 Jun 2227-4217031 Mar 2227-4717031 Dec 2131-4617030 Sep 2125-5116030 Jun 2124-4816031 Mar 2132-3816031 Dec 2029-3717030 Sep 2045-2618030 Jun 2057-1518031 Mar 2051-2218031 Dec 1946-2818030 Sep 1934-36191330 Jun 1927-40182431 Mar 1933-28193431 Dec 1829-27184130 Sep 1842-8213330 Jun 1838-8192831 Mar 1828-18182431 Dec 1725-18182230 Sep 1710-32142330 Jun 177-31132231 Mar 176-27112131 Dec 166-2391930 Sep 165-1991530 Jun 165-1791331 Mar 164-1581031 Dec 153-149830 Sep 154-1510730 Jun 154-138631 Mar 154-139631 Dec 145-107530 Sep 146-55531 Dec 1312039양질의 수익: PIRS 은(는) 현재 수익성이 없습니다.이익 마진 증가: PIRS는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PIRS는 수익성이 없지만 지난 5년 동안 연평균 5.2%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PIRS의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PIRS은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PIRS는 현재 수익성이 없으므로 자본 수익률이 음수(-98.06%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/12/16 02:03종가2024/12/13 00:00수익2024/09/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pieris Pharmaceuticals, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullBairdMichael KingCitizens JMP Securities, LLCJoseph PantginisH.C. Wainwright & Co.7명의 분석가 더 보기
Reported Earnings • Nov 15Third quarter 2024 earnings released: US$2.19 loss per share (vs US$8.70 loss in 3Q 2023)Third quarter 2024 results: US$2.19 loss per share (improved from US$8.70 loss in 3Q 2023). Net loss: US$2.89m (loss narrowed 73% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 16Second quarter 2024 earnings released: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)Second quarter 2024 results: US$2.76 loss per share (down from US$3.63 profit in 2Q 2023). Net loss: US$3.59m (down 190% from profit in 2Q 2023).
Reported Earnings • May 17First quarter 2024 earnings released: US$3.96 loss per share (vs US$14.15 loss in 1Q 2023)First quarter 2024 results: US$3.96 loss per share (improved from US$14.15 loss in 1Q 2023). Revenue: US$53.0k (down 97% from 1Q 2023). Net loss: US$4.89m (loss narrowed 63% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 31Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)Full year 2023 results: US$0.27 loss per share (improved from US$0.45 loss in FY 2022). Revenue: US$42.8m (up 65% from FY 2022). Net loss: US$24.5m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 17Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2023 results: US$0.11 loss per share. Revenue: US$19.5m (up 264% from 3Q 2022). Net loss: US$10.8m (loss widened 10% from 3Q 2022). Revenue is expected to decline by 81% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%.
Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$0.045 (up from US$0.14 loss in 2Q 2022). Revenue: US$20.1m (up 442% from 2Q 2022). Net income: US$3.98m (up US$14.3m from 2Q 2022). Profit margin: 20% (up from net loss in 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 17% during the next year, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 15Third quarter 2024 earnings released: US$2.19 loss per share (vs US$8.70 loss in 3Q 2023)Third quarter 2024 results: US$2.19 loss per share (improved from US$8.70 loss in 3Q 2023). Net loss: US$2.89m (loss narrowed 73% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
공시 • Nov 07Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024.
Reported Earnings • Aug 16Second quarter 2024 earnings released: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)Second quarter 2024 results: US$2.76 loss per share (down from US$3.63 profit in 2Q 2023). Net loss: US$3.59m (down 190% from profit in 2Q 2023).
공시 • Jul 25Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction.Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction on July 23, 2024. The provisions for calculating the Exchange Ratio are set forth in the Merger Agreement and assume a valuation for Palvella equal to $95.0 million and a valuation for Pieris equal to $21.0 million. Under the terms of the merger agreement, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. Upon termination of the Merger Agreement under specified circumstances, Pieris may be required to pay Palvella a termination fee of $1.0 million and Palvella may be required to pay Pieris a termination fee of $2.0 million. The transactions contemplated by the merger agreement have been unanimously approved by the boards of directors of both companies. The transaction is subject to approvals by the stockholders of each company, consummation of the Concurrent Financing, the effectiveness of a registration statement to be filed with the SEC to register the shares of Pieris common stock to be issued in connection with the merger, and other customary closing conditions. TD Cowen is serving as lead placement agent and Cantor is serving as a placement agent for Palvella's planned concurrent financing. Christopher S. Miller of Troutman Pepper Hamilton Sanders LLP is serving as legal counsel to Palvella. Cooley LLP is serving as legal counsel to the placement agents. Stifel is serving as the exclusive financial advisor to Pieris and William C. Hicks, Marc D. Mantell and Scott Dunberg of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. is serving as legal counsel to Pieris. Stifel, Nicolaus & Company, Incorporated acted as fairness opinion provider to Pieris. Computershare Trust Company, National Association acted as transfer agent to Pieris.
New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 27% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (US$10.5m market cap).
분석 기사 • Jul 11The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%Unfortunately for some shareholders, the Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has dived 30% in the...
Reported Earnings • May 17First quarter 2024 earnings released: US$3.96 loss per share (vs US$14.15 loss in 1Q 2023)First quarter 2024 results: US$3.96 loss per share (improved from US$14.15 loss in 1Q 2023). Revenue: US$53.0k (down 97% from 1Q 2023). Net loss: US$4.89m (loss narrowed 63% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 21Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price PlungePieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders won't be pleased to see that the share price has had a very...
공시 • Apr 21Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price RequirementPieris Pharmaceuticals, Inc. announced that its board of directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's existing trading symbol ‘PIRS’. The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 720795202. The Company filed a Certificate of Change with the Nevada Secretary of State on April 18, 2024 to effect the reverse split.
Reported Earnings • Mar 31Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)Full year 2023 results: US$0.27 loss per share (improved from US$0.45 loss in FY 2022). Revenue: US$42.8m (up 65% from FY 2022). Net loss: US$24.5m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 19We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
분석 기사 • Dec 18Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%Unfortunately for some shareholders, the Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has dived 27% in the...
Reported Earnings • Nov 17Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2023 results: US$0.11 loss per share. Revenue: US$19.5m (up 264% from 3Q 2022). Net loss: US$10.8m (loss widened 10% from 3Q 2022). Revenue is expected to decline by 81% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%.
분석 기사 • Aug 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: US$0.045 (up from US$0.14 loss in 2Q 2022). Revenue: US$20.1m (up 442% from 2Q 2022). Net income: US$3.98m (up US$14.3m from 2Q 2022). Profit margin: 20% (up from net loss in 2Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 17% during the next year, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
공시 • Jul 14Pieris Pharmaceuticals, Inc. Announces Executive ChangesPieris Pharmaceuticals, Inc. announced on July 13, 2023, Ahmed Mousa, the Senior Vice President, Chief Business Officer, General Counsel & Corporate Secretary of the company, gave notice that he will resign from the company effective September 11, 2023 in order to become chief executive officer of Vicore Pharma Holding AB. Mr. Mousa is expected to serve as a strategic advisor to the Company for a transition period thereafter, subject to a mutual agreement of terms in the near future. Mr. Mousa’s resignation is not a result of any disagreement with the Company or any other entity or on any matter relating to the operations, policies (including accounting or financial policies) or practices of the company. Following Mr. Mousa’s departure, Stephen Yoder, the company’s chief executive officer and President will oversee corporate and business development at the company.
New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$49m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 8.5% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$13.6m market cap).
New Risk • Jun 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 8.5% per year for the foreseeable future. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$49m). Currently unprofitable and not forecast to become profitable over next 3 years (US$74m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (US$21.4m market cap).
공시 • May 22+ 1 more updatePieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International ConferencePieris Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company's inhaled connective tissue growth factor (CTGF) antagonist program, PRS-220, for idiopathic pulmonary fibrosis (IPF) at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023. The poster will be presented on May 21, 2023, from 11:30 AM to 1:15 PM (Session A67, P1052) and demonstrates that PRS-220 achieved proof of concept in a silica-induced lung fibrosis mouse model when delivered to the lung by inhalation and outperformed a systemically administered CTGF-targeting monoclonal antibody, reinforcing the transformative potential of a local intervention in this pathway. The poster also includes preclinical data demonstrating a favorable profile of PRS-220 for inhaled delivery and CTGF targeting in the lung, including a superior lung biodistribution profile compared to a systemically administered anti-CTGF monoclonal antibody, a lung PK profile supporting once or twice daily dosing in humans, and desired aerosol performance upon nebulization to effectively target pulmonary tissue of interest. PRS-220 is an inhaled Anticalin protein targeting CTGF for the treatment of IPF and other fibrotic lung diseases. Previously reported preclinical data for PRS-220 demonstrated superior on-target potency compared to pamrevlumab, an intravenously infused CTGF antagonist in late-stage clinical development. Pieris continues to benefit from a meaningful grant from the Bavarian government, which supports early-stage development of this program.
Major Estimate Revision • May 17Consensus revenue estimates fall by 31%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$17.4m to US$12.0m. Forecast losses increased from -US$0.64 to -US$0.705 per share. Biotechs industry in the US expected to see average net income decline 85% next year. Consensus price target of US$7.00 unchanged from last update. Share price fell 6.0% to US$0.80 over the past week.
분석 기사 • May 15Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts DramaticallyThe latest analyst coverage could presage a bad day for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), with the analysts...
Reported Earnings • May 10First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)First quarter 2023 results: US$0.18 loss per share (further deteriorated from US$0.069 loss in 1Q 2022). Revenue: US$1.94m (down 82% from 1Q 2022). Net loss: US$13.2m (loss widened 158% from 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
공시 • May 05Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)Pieris Pharmaceuticals, Inc. announced the successful safety review of the 10 mg dry powder dose safety cohort from the ongoing multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated elarekibep (PRS-060/AZD1402). The successful review of the 10 mg dose provides additional data supporting the elarekibep safety profile and enables doses of 10 mg or less to be evaluated in future clinical trials. Elarekibep is an IL-4 receptor alpha inhibitor under development in collaboration with AstraZeneca for the treatment of moderate-to-severe asthma. Pieris previously announced the successful completion of the safety review for the 1 mg and 3 mg doses, triggering the efficacy portion of the study, which is ongoing at the 3 mg dose. Upon completion of the phase 2a study and availability of topline data, which Pieris expects to be reported by mid-2024, the Company will have a co-development option for this program with AstraZeneca. For this safety review, 13 asthma patients, controlled on standard of care (medium dose inhaled corticosteroids with long-acting beta agonists), received elarekibep twice daily over four weeks to establish the safety profile and pharmacokinetics of the dry powder formulation of elarekibep at the 10 mg dose. Following completion of enrollment and observation, AstraZeneca evaluated, compared to placebo, the incidence of adverse events, changes in laboratory markers (immuno-biomarkers, clinical chemistry, and hematology), and forced expiratory volume in one second.
분석 기사 • Apr 17Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price PlungeThe Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) share price has fared very poorly over the last month, falling by a...
Reported Earnings • Mar 31Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)Full year 2022 results: US$0.45 loss per share (improved from US$0.71 loss in FY 2021). Revenue: US$25.9m (down 18% from FY 2021). Net loss: US$33.3m (loss narrowed 27% from FY 2021). Products in clinical trials Phase I: 3 Phase II: 1 Revenue is expected to decline by 41% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 13%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
공시 • Jan 11Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)Pieris Pharmaceuticals, Inc. announced that the Company has achieved a $5 million milestone from Seagen. The milestone is based on dosing the first patient in a Seagen-sponsored phase 1 study of SGN-BB228 (PRS-346), a novel bispecific antibody-Anticalin molecule (Mabcalin™) that is designed to provide a potent costimulatory bridge between tumor-specific T cells and CD228 expressing tumor cells. The Seagen-sponsored (NCT05571839) open-label phase 1 study is evaluating the safety and tolerability of SGN-BB228 in patients with advanced melanoma and other solid tumors. Secondary endpoints in the study include pharmacokinetics and antitumor activity. This program is one of three ongoing immuno-oncology programs with Seagen and preclinical data were recently presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston. Pieris has an opt-in option to a U.S. co-promotion for one program in the collaboration.
분석 기사 • Dec 31Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Price Target Changed • Nov 16Price target decreased to US$7.00Down from US$8.00, the current price target is provided by 1 analyst. New target price is 593% above last closing price of US$1.01. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$0.47 next year compared to a net loss per share of US$0.71 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 03Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: US$0.13 loss per share (improved from US$0.24 loss in 3Q 2021). Revenue: US$5.37m (up 32% from 3Q 2021). Net loss: US$9.74m (loss narrowed 41% from 3Q 2021). Revenue is expected to decline by 17% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
Major Estimate Revision • Aug 11Consensus revenue estimates fall by 48%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$45.7m to US$23.7m. Forecast losses increased from -US$0.41 to -US$0.47 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target down from US$8.00 to US$7.00. Share price fell 9.3% to US$1.56 over the past week.
분석 기사 • Aug 10Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS PrognosticationsThe latest analyst coverage could presage a bad day for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), with the covering...
Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: US$0.14 loss per share (up from US$0.25 loss in 2Q 2021). Revenue: US$3.70m (up 13% from 2Q 2021). Net loss: US$10.3m (loss narrowed 33% from 2Q 2021). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Over the next year, revenue is expected to shrink by 45% compared to a 46% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
Seeking Alpha • Aug 04Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77MPieris Pharmaceuticals press release (NASDAQ:PIRS): Q2 GAAP EPS of -$0.14 misses by $0.03. Revenue of $3.7M (+12.5% Y/Y) misses by $6.77M. Cash, equivalents, and investments totaled $80.9 million for the quarter ended June 30, 2022, compared to a cash and cash equivalents balance of $117.8 million for the quarter ended December 31, 2021.. Shares +4.95% PM.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.069 loss per share. Revenue: US$11.0m (down 30% from 1Q 2021). Net loss: US$5.10m (loss widened 22% from 1Q 2021). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 72%, compared to a 25% growth forecast for the industry in the US.
Major Estimate Revision • May 12Consensus estimates of losses per share improve by 23%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from US$45.2m to US$45.7m. EPS estimate increased from -US$0.53 per share to -US$0.41 per share. Biotechs industry in the US expected to see average net income decline 44% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 34% to US$1.67 over the past week.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 03Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.71 loss per share (down from US$0.68 loss in FY 2020). Revenue: US$31.4m (up 7.1% from FY 2020). Net loss: US$45.7m (loss widened 23% from FY 2020). Revenue exceeded analyst estimates by 23%. Earnings per share (EPS) missed analyst estimates by 19%. Over the next year, revenue is forecast to grow 125%, compared to a 71% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Seeking Alpha • Jan 09Pieris: Early Stage Developer Of Novel Asset ClassPieris develops anticalin-based therapies. These are proteins that are smaller than most, enabling inhaled formulations and better tissue penetration. A number of big pharma are interested.
분석 기사 • Dec 15We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: US$4.06m (up 38% from 3Q 2020). Net loss: US$16.5m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Board Change • Nov 03Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Maya Said was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Oct 27Progress At Pieris PharmaceuticalsToday, we revisit a promising small cap biopharma concern named Pieris Pharmaceuticals for the first time in just over two years. The company has made some progress advancing its pipeline and recently signed a potentially significant collaboration deal with Genentech. A full investment analysis follows in the paragraphs below.
Reported Earnings • Aug 08Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$3.29m (down 71% from 2Q 2020). Net loss: US$15.5m (loss widened 213% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Major Estimate Revision • Aug 05Consensus revenue estimates increase to US$32.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$21.8m to US$32.5m. Forecast losses expected to reduce from -US$0.90 to -US$0.78 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target of US$8.50 unchanged from last update. Share price rose 9.9% to US$3.76 over the past week.
분석 기사 • Aug 05Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) ForecastsShareholders in Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) may be thrilled to learn that the analysts have just...
Price Target Changed • Jul 06Price target increased to US$8.50Up from US$7.50, the current price target is an average from 3 analysts. New target price is 132% above last closing price of US$3.66. Stock is up 13% over the past year.
공시 • Jun 28Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth IndexPieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index
분석 기사 • Jun 19We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A MicroscopeShareholders will probably not be too impressed with the underwhelming results at Pieris Pharmaceuticals, Inc...
Major Estimate Revision • May 24Consensus revenue estimates fall to US$22.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$29.7m to US$22.0m. Forecast losses increased from -US$0.69 to -US$0.90 per share. Biotechs industry in the US expected to see average net income decline 7.2% next year. Consensus price target down from US$9.00 to US$7.50. Share price was steady at US$1.93 over the past week.
분석 기사 • May 22Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) EstimatesMarket forces rained on the parade of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders today, when the...
Price Target Changed • May 20Price target decreased to US$7.50Down from US$9.00, the current price target is an average from 2 analysts. New target price is 308% above last closing price of US$1.84. Stock is down 40% over the past year.
분석 기사 • May 19Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • May 18First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$15.6m (up 18% from 1Q 2020). Net loss: US$4.17m (loss widened 16% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Apr 01Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$29.3m (down 37% from FY 2019). Net loss: US$37.2m (loss widened 32% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
분석 기사 • Apr 01Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This WeekCelebrations may be in order for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) shareholders, with the analysts...
Is New 90 Day High Low • Mar 09New 90-day low: US$2.41The company is down 11% from its price of US$2.70 on 08 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$1.60 per share.
분석 기사 • Mar 08Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks LikeEvery investor in Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) should be aware of the most powerful shareholder groups...
Is New 90 Day High Low • Feb 11New 90-day high: US$3.19The company is up 20% from its price of US$2.65 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period.
분석 기사 • Feb 01We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Price Target Changed • Jan 30Price target raised to US$9.00Up from US$8.00, the current price target is an average from 4 analysts. The new target price is 254% above the current share price of US$2.54. As of last close, the stock is down 31% over the past year.
분석 기사 • Dec 28How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?While it may not be enough for some shareholders, we think it is good to see the Pieris Pharmaceuticals, Inc...
Is New 90 Day High Low • Dec 16New 90-day high: US$3.13The company is up 9.0% from its price of US$2.88 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
분석 기사 • Dec 02How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?Steve Yoder has been the CEO of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) since 2014, and this article will examine...
Major Estimate Revision • Nov 11Analysts lower revenue estimates to US$30.5mThe 2020 consensus revenue estimate decreased from US$42.0m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$0.48 to -US$0.64 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.6% next year. The consensus price target was lowered from US$8.00 to US$7.67. Share price is up 13% to US$2.82 over the past week.
Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.26 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$2.94m (down 81% from 3Q 2019). Net loss: US$14.3m (loss widened 451% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
Analyst Estimate Surprise Post Earnings • Nov 07Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 80%. Earnings per share (EPS) exceeded analyst estimates by 111%. Over the next year, revenue is expected to shrink by 32% compared to a 309% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Sep 22New 90-day low: US$2.33The company is down 28% from its price of US$3.22 on 24 June 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.